Valproate (Epilepsy)

Spina bifida

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S8138
R24995
Charlton (Valproate) (Controls exposed to Lamotrigine, sick), 2011 Spina bifida 1st trimester retrospective cohort (claims database) exposed to other treatment, sick excluded Adjustment: No 3.98 [0.21;74.64] C
excluded (control group)
4/225   0/98 4 225
ref
S8136
R24989
Charlton (Valproate) (Controls unexposed, sick), 2011 Spina bifida 1st trimester retrospective cohort (claims database) unexposed, sick Adjustment: No 8.02 [1.50;43.50] 4/225   2/902 6 225
ref
S6168
R16230
Viinikainen (Valproate) (Controls unexposed, sick) a, 2006 Spina bifida throughout pregnancy prospective cohort unexposed, sick Adjustment: No 5.83 [0.23;148.09] C 1/28   0/52 1 28
ref
S6099
R15903
Artama (Valproate), 2005 Spina bifida 1st trimester retrospective cohort (registry) unexposed, sick Adjustment: No 40.09 [2.21;727.45] C 5/263   0/939 5 263
ref
S8414
R26714
Källén (Valproate), 1994 Spina bifida during pregnancy (anytime or not specified) excluded nested case control unexposed, sick Adjustment: No Matched no data
excluded (exposition period)
1/1   0/6 1 1
ref
S6491
R17781
Czeizel (Valproate), 1992 Spina bifida throughout pregnancy case control unexposed, sick Adjustment: No 3.00 [0.08;107.45] C 1/2   1/4 2 2
ref
Total 4 studies 9.14 [2.63;31.73] 14 518
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Charlton (Valproate) (Controls unexposed, sick), 2011Charlton, 2011 1 8.02[1.50; 43.50]622555%ROB confusion: criticalROB selection: moderateROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Viinikainen (Valproate) (Controls unexposed, sick) a, 2006Viinikainen, 2006 2 5.83[0.23; 148.09]12815%ROB confusion: criticalROB selection: moderateROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Artama (Valproate), 2005Artama, 2005 3 40.09[2.21; 727.45]526318%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Czeizel (Valproate), 1992Czeizel, 1992 4 3.00[0.08; 107.45]2212%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (4 studies) I2 = 0% 9.14[2.63; 31.73]145180.9100.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Valproate) (Controls unexposed, sick; 2: Valproate) (Controls unexposed, sick) ; 3: Valproate; 4: Valproate;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 10.65[2.82; 40.18]125160%NACharlton (Valproate) (Controls unexposed, sick), 2011 Viinikainen (Valproate) (Controls unexposed, sick) a, 2006 Artama (Valproate), 2005 3 case control studiescase control studies 3.00[0.08; 107.45]22 -NACzeizel (Valproate), 1992 1 Type of controls unexposed, sickunexposed, sick 9.14[2.63; 31.73]145180%NACharlton (Valproate) (Controls unexposed, sick), 2011 Viinikainen (Valproate) (Controls unexposed, sick) a, 2006 Artama (Valproate), 2005 Czeizel (Valproate), 1992 4 Tags Adjustment   - No  - No 9.14[2.63; 31.73]145180%NACharlton (Valproate) (Controls unexposed, sick), 2011 Viinikainen (Valproate) (Controls unexposed, sick) a, 2006 Artama (Valproate), 2005 Czeizel (Valproate), 1992 4 All studiesAll studies 9.14[2.63; 31.73]145180%NACharlton (Valproate) (Controls unexposed, sick), 2011 Viinikainen (Valproate) (Controls unexposed, sick) a, 2006 Artama (Valproate), 2005 Czeizel (Valproate), 1992 40.5100.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-4.46.52.1910.000Charlton (Valproate) (Controls unexposed, sick), 2011Viinikainen (Valproate) (Controls unexposed, sick) a, 2006Artama (Valproate), 2005Czeizel (Valproate), 1992

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded 8138

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls 9.14[2.63; 31.73]145180%NACharlton (Valproate) (Controls unexposed, sick), 2011 Viinikainen (Valproate) (Controls unexposed, sick) a, 2006 Artama (Valproate), 2005 Czeizel (Valproate), 1992 4 exposed to other treatment, sick controlsexposed to other treatment, sick controls 3.98[0.21; 74.64]4225 -NACharlton (Valproate) (Controls exposed to Lamotrigine, sick), 2011 10.510.01.0